OrthoPediatrics Corp. (KIDS)

In the past six months, OrthoPediatrics Corp. announced preliminary third-quarter 2025 revenue and revised its 2025 guidance, reported its third-quarter 2025 financial results, announced record preliminary unaudited revenue for the full year 2025 and issued its financial guidance for 2026, and reported its fourth-quarter and full-year 2025 financial results. During the fourth quarter of 2025 earnings, the company missed EPS expectations but beat revenue expectations. The stock price has seen a decline, insider selling has been observed, and short interest in the stock recently increased. Analysts have a "Moderate Buy" consensus rating for KIDS, with an average price target of $24.67.

Demand for OrthoPediatrics Corp.'s products and services exhibits seasonality, with summer surgery seasons typically being larger months. The company anticipates that its EBITDA and free cash flow will follow similar quarterly seasonality patterns as in 2025, with some periods being negative and others positive, but cumulatively tracking towards annual guidance metrics.

OrthoPediatrics Corp. is a medical device company focused on designing, developing, and marketing orthopedic implants, instruments, and specialized braces for children. The company operates in the Healthcare sector, specifically the Medical Devices industry, and offers over 85 products across pediatric trauma and deformity correction, scoliosis procedures, and sports medicine.

OrthoPediatrics Corp. distributes its products in the United States through a direct sales organization and in over 75 countries internationally via distributors and regional offices in Europe, Latin America, and the Asia-Pacific region.

OrthoPediatrics Corp. maintains a positive brand reputation due to its exclusive focus on pediatric orthopedics and its mission to improve the lives of children with orthopedic conditions. The company reported helping over 37,500 children in the fourth quarter of 2025 alone, bringing its total impact to nearly 1.3 million children since its inception.

OrthoPediatrics Corp. has a significant portion of its shares held by institutional and individual owners. Major institutional shareholders include Brown Advisory Inc, Millennium Management Llc, BlackRock, Inc., Morgan Stanley, Braidwell Lp, Wellington Management Group Llp, Vanguard Group Inc, Dimensional Fund Advisors Lp, Soleus Capital Management, L.P., Brown Capital Management Llc, D. E. Shaw & Co., Inc., Ra Capital Management, L.p., Point72 Asset Management, L.P., AWM Investment Company, Inc., State Street Corp., and SEI Investments Co. Institutional shareholders collectively hold 64.53% of the company's stock. Squadron Capital LLC is also a major shareholder, holding 27.52% of the equities. David R. Pelizzon is the largest individual shareholder, owning 13.84 million shares, which represents 54.74% of the company. Insiders collectively own 87.91% of the company.